154 related articles for article (PubMed ID: 22025155)
1. Progress in molecular targeted therapy for thyroid cancer: vandetanib in medullary thyroid cancer.
Solomon B; Rischin D
J Clin Oncol; 2012 Jan; 30(2):119-21. PubMed ID: 22025155
[No Abstract] [Full Text] [Related]
2. Vandetanib (Caprelsa) for medullary thyroid cancer.
Med Lett Drugs Ther; 2012 Jan; 54(1381):3-4. PubMed ID: 22233588
[No Abstract] [Full Text] [Related]
3. Vandetanib-associated alopecia areata in a patient with metastatic medullary thyroid cancer.
Jalalat SZ; Cohen PR
Int J Dermatol; 2015 Jun; 54(6):e213-6. PubMed ID: 25040327
[No Abstract] [Full Text] [Related]
4. Use of Vandetanib in Metastatic Medullary Carcinoma of Thyroid in a Pediatric Patient With Multiple Endocrine Neoplasia 2B.
Narayanan VK; Ronghe M; MacGregor FB; Bradshaw N; Davidson R; Welbury R; Reed N; Shaikh MG
J Pediatr Hematol Oncol; 2016 Mar; 38(2):155-7. PubMed ID: 26479990
[TBL] [Abstract][Full Text] [Related]
5. Pregnancy on vandetanib in metastatic medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2B.
Thomas N; Glod J; Derse-Anthony C; Baple EL; Osborne N; Sturley R; Vaidya B; Newbold K; Brooke A
Clin Endocrinol (Oxf); 2018 May; 88(5):754-756. PubMed ID: 29457255
[No Abstract] [Full Text] [Related]
6. Disseminated medullary thyroid cancer - an alternative therapeutic approach.
Wilczyńska M; Suchmiel M; Sokołowski G; Hubalewska-Dydejczyk A; Trofimiuk-Müldner M
Endokrynol Pol; 2022; 73(5):909-910. PubMed ID: 35971935
[TBL] [Abstract][Full Text] [Related]
7. Vandetanib: a guide to its use in advanced medullary thyroid cancer.
Keating GM; Lyseng-Williamson KA; Frampton JE
BioDrugs; 2012 Dec; 26(6):431-5. PubMed ID: 22938056
[TBL] [Abstract][Full Text] [Related]
8. Use of Neoadjuvant Vandetanib in Aggressive Pediatric Medullary Thyroid Carcinoma.
Kothari R; Kreimer S; Nadel H; Seeley H; Hartman G; Meister KD
JCO Precis Oncol; 2024 Jan; 8():e2300257. PubMed ID: 38207224
[TBL] [Abstract][Full Text] [Related]
9. Completing the Arc: targeted inhibition of RET in medullary thyroid cancer.
Houvras Y
J Clin Oncol; 2012 Jan; 30(2):200-2. PubMed ID: 22162569
[No Abstract] [Full Text] [Related]
10. [Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].
Chougnet CN; Schlumberger M; Leboulleux S; Baudin E
Bull Cancer; 2014 Sep; 101(9):891-5. PubMed ID: 25296193
[TBL] [Abstract][Full Text] [Related]
11. Reversal of Cushing's syndrome by vandetanib in medullary thyroid carcinoma.
Baudry C; Paepegaey AC; Groussin L
N Engl J Med; 2013 Aug; 369(6):584-6. PubMed ID: 23924025
[No Abstract] [Full Text] [Related]
12. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
[TBL] [Abstract][Full Text] [Related]
13. Vandetanib Tumor Shrinkage in Metastatic Medullary Thyroid Cancer Allowing Surgical Resection of the Primary Site: A Case Report.
Milner TD; Ronghe M; Shaikh MG; MacGregor FB; Reed N
J Pediatr Hematol Oncol; 2019 Jul; 41(5):e329-e332. PubMed ID: 30334899
[TBL] [Abstract][Full Text] [Related]
14. Vandetanib for the treatment of medullary thyroid carcinoma.
Cooper MR; Yi SY; Alghamdi W; Shaheen DJ; Steinberg M
Ann Pharmacother; 2014 Mar; 48(3):387-94. PubMed ID: 24259657
[TBL] [Abstract][Full Text] [Related]
15. The safety of vandetanib for the treatment of thyroid cancer.
Tsang VH; Robinson BG; Learoyd DL
Expert Opin Drug Saf; 2016 Aug; 15(8):1107-13. PubMed ID: 27301016
[TBL] [Abstract][Full Text] [Related]
16. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.
Fallahi P; Ferrari SM; Baldini E; Biricotti M; Ulisse S; Materazzi G; Miccoli P; Antonelli A
Expert Rev Anticancer Ther; 2016 Nov; 16(11):1109-1118. PubMed ID: 27650489
[TBL] [Abstract][Full Text] [Related]
17. Kinase inhibitors for advanced medullary thyroid carcinoma.
Schlumberger M; Massicotte MH; Nascimento CL; Chougnet C; Baudin E; Leboulleux S
Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):125-9. PubMed ID: 22584717
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy: vandetanib-a new therapeutic option in advanced medullary thyroid cancer.
Koch L
Nat Rev Endocrinol; 2011 Nov; 8(1):1. PubMed ID: 22083086
[No Abstract] [Full Text] [Related]
19. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
[No Abstract] [Full Text] [Related]
20. Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.
Del Rivero J; Edgerly M; Ward J; Madan RA; Balasubramaniam S; Fojo T; Gramza AW
Oncologist; 2019 Jan; 24(1):16-e14. PubMed ID: 30297385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
